EUVIMEDEUVIMED entdecken
Studienprotokoll

Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)

Weiping Jia iD, Qinghua Wang iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70556 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Weiping Jia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Clinical Ce…. Hauptthemen laut MEDLINE: Obesity, Overweight, Anti-Obesity Agents. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Innogen Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To describe the design and rationale of LIGHT 2, a seamless, adaptive phase 2b/3 trial evaluating the efficacy and safety of efsubaglutide alfa for chronic weight management in adults with overweight or obesity. Materials and Methods LIGHT 2 is a multicentre, randomized, double‐blind, placebo‐controlled study in which eligible participants are assigned to efsubaglutide alfa dose regimens or matched placebo. Efsubaglutide alfa is administered with a prespecified dose‐escalation scheme to target maintenance doses delivered once weekly or once every 2 weeks. The seamless, adaptive framework enables interim evaluation to support regimen selection and progression to the confirmatory phase under a single protocol with maintained blinding and centralized oversight. An independent data monitoring committee reviews interim safety and adaptive decisions per a prespecified charter.

Results

The primary efficacy endpoint is percentage change in body weight. Key secondary endpoints include categorical weight‐loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments; an imaging substudy will further characterize effects on ectopic fat in a subset of participants.

Conclusions

LIGHT 2 is designed to efficiently identify and confirm an efsubaglutide alfa regimen with clinically meaningful weight‐loss efficacy and an acceptable safety profile, while generating evidence relevant to real‐world implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityOverweightAnti-Obesity AgentsHumansDouble-Blind MethodAdultClinical Trials, Phase II as TopicFemaleMulticenter Studies as TopicMaleWeight LossRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

efsubaglutide alfaglucagon‐like peptide‐1 receptor agonistobesityoverweightweight management

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laborator…
  • Innogen Pharmaceutical Technology Co., Ltd, Shanghai, China.
  • Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.

ORCID-Profile: Weiping Jia, Qinghua Wang

Förderung

  • Innogen Pharmaceutical Co. Ltd.

Zitieren

APA

Jia, W., & Wang, Q. (2026). Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70556

Vancouver

Jia W, Wang Q. Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2). Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70556

BibTeX
@article{Jia2026,
  author = {Jia, Weiping and Wang, Qinghua},
  title = {Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70556}
}
Kostenlos starten →